HEMAB THERAPEUTICS ($COAG) posted quarterly earnings results for Q3 2026 on Tuesday, November 10th. The company reported earnings of -$0.58 per share, missing estimates of -$0.53 by $0.05. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $COAG stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
HEMAB THERAPEUTICS Insider Trading Activity
HEMAB THERAPEUTICS insiders have traded $COAG stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $COAG stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT, L.P. RA has made 5 purchases buying 78,854 shares for an estimated $1,968,630 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
HEMAB THERAPEUTICS Hedge Fund Activity
We have seen 57 institutional investors add shares of HEMAB THERAPEUTICS stock to their portfolio, and 2 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. added 7,808,627 shares (+inf%) to their portfolio in Q2 2026, for an estimated $286,810,869
- NOVO HOLDINGS A/S added 4,180,550 shares (+inf%) to their portfolio in Q2 2026, for an estimated $153,551,601
- FMR LLC added 3,697,837 shares (+inf%) to their portfolio in Q2 2026, for an estimated $135,821,553
- CAPITAL INTERNATIONAL INVESTORS added 3,603,876 shares (+inf%) to their portfolio in Q2 2026, for an estimated $132,370,365
- DEEP TRACK CAPITAL, LP added 3,602,093 shares (+inf%) to their portfolio in Q2 2026, for an estimated $132,304,875
- SIREN, L.L.C. added 2,086,834 shares (+inf%) to their portfolio in Q2 2026, for an estimated $76,649,412
- AVORO CAPITAL ADVISORS LLC added 1,925,150 shares (+inf%) to their portfolio in Q2 2026, for an estimated $70,710,759
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
HEMAB THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $COAG recently. We have seen 5 analysts offer price targets for $COAG in the last 6 months, with a median target of $40.0.
Here are some recent targets:
- Emily Bodnar from HC Wainwright & Co. set a target price of $40.0 on 06/26/2026
- Richard Law from Goldman Sachs set a target price of $36.0 on 05/26/2026
- Maury Raycroft from Jefferies set a target price of $39.0 on 05/26/2026
- Cory Kasimov from Evercore ISI Group set a target price of $50.0 on 05/26/2026
- David Nierengarten from Wedbush set a target price of $42.0 on 05/26/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.